[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100533528":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":19,"locations":25,"responsibleParty":43,"collaborators":47,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":10,"eligibilityCriteria":56,"healthyVolunteers":53,"sex":57,"minAge":58,"maxAge":10,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":10,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"University of Cambridge","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Fabry Disease with cardiac involvement",null,[12],"Diagnostic Test: 68Ga-DOTATATE PET\u002FMRI",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DIAGNOSTIC_TEST","68Ga-DOTATATE PET\u002FMRI","PET\u002FMRI scanning",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Jason M Tarkin, PhD MBBS","CONTACT","+44(0)1223331504","jt545@cam.ac.uk",[26],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Cambridge University Hospital NHS Foundation Trust","RECRUITING","Cambridge","Cambridgeshire","CB2 0QQ","United Kingdom","UK",{"type":35,"coordinates":36},"Point",[37,38],0.11667,52.2,{"lat":38,"lon":37},[41],{"name":42,"role":22,"phone":10,"phoneExt":10,"email":10},"Patrick Deegan, MD",{"type":44,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Jason Tarkin","Wellcome Clinical Research Career Development Fellow & Honorary Consultant Cardiologist",[48],{"name":49,"class":50},"Sanofi","INDUSTRY","100533528","molecular-imaging-in-fabry-disease-of-the-heart-100533528",false,"NCT06226987","Molecular Imaging in Fabry Disease of the Heart","Inclusion Criteria:\n\n* Male or female participants \\>18 years old\n* Able to give written, informed consent and to lie flat\n* Have Fabry disease based on molecular diagnosis (at a minimum, documented enzyme deficiency in males and documented pathogenic mutation in females)\n* Cardiac MRI within 3 years documenting cardiac involvement in Fabry disease (left ventricular hypertrophy and\u002For late gadolinium enhancement and\u002For myocardial oedema)\n\nExclusion Criteria:\n\n* Any other diagnosis associated with cardiac muscle inflammation, including myocarditis\n* Previous gene therapy\n* Contra-indication to MRI scanning or intravenous gadolinium contrast (prior contrast reaction or chronic kidney disease with eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2)\n* Women of child bearing potential not using adequate contraception\n* Uncontrolled atrial fibrillation\n* Any medical condition, in the opinion of the investigator, that prevents the participant from lying flat during scanning, or from participating in the study","ALL","18 Years",{"count":60,"type":61},12,"ESTIMATED","OBSERVATIONAL","Better methods for early detection of cardiac involvement in Fabry disease are needed to inform clinical management decisions that can help prevent or slow the progression of cardiac complications. In the Molecular Imaging of Inflammation in Fabry Disease of the Heart study, the investigators will test the use of 68Ga-DOTATATE PET\u002FMRI for identifying myocardial inflammation in patients with Fabry disease.",[65],"Fabry Disease, Cardiac Variant","2024-07-18",{"date":68,"type":69},"2024-07-22","ACTUAL",{"date":71,"type":69},"2024-01-02",{"date":73,"type":61},"2026-01-02",{"name":5,"class":6},1]